MANNKIND CORP
Close on Oct 19, 2026
- Market cap
- $955.40M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | $109.40M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | $90.17M | $-0.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $111.96M | $-0.05 | $0.01 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | – | – | $0.05 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $78.35M | $0.04 | $0.07 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | During market hours | $76.78M | $0.03 | $0.08 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $70.00M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | During market hours | – | – | – |
Press releases
Announcements Mannkind filed with the SEC
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
MannKind Announces $50 Million Private Placement
Unregistered share sale · Other events · EX-99.1 to Form 8-K
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
THIRD QUARTER 2025 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
scPharmaceuticals August 25, 2025 Exhibit 99.2
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
SECOND QUARTER 2025 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
FIRST QUARTER 2025 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
2024 THIRD QUARTER FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
2024 SECOND QUARTER FINANCIAL RESULTS:
Results of operations · EX-99.1 to Form 8-K
2024 FIRST QUARTER FINANCIAL RESULTS:
Results of operations · EX-99.1 to Form 8-K
2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE
Results of operations · EX-99.1 to Form 8-K
2023 THIRD QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
2023 SECOND QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
2023 FIRST QUARTER FINANCIAL RESULTS
Results of operations · EX-99 to Form 8-K/A
2023 FIRST QUARTER FINANCIAL RESULTS
Results of operations · EX-99 to Form 8-K
LAUREN SABELLA JOINS MANNKIND AS EXECUTIVE
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
2022 THIRD QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
2022 SECOND QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
PLATFORM UTILIZED IN FDA-APPROVED TYVASO DPI™
Other events · EX-99.1 to Form 8-K
2022 FIRST QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
2021 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
2021 THIRD QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K